In line with this, bardoxolone reduces body weight in patients with diabetes, suggesting that proteins that regulate metabolic pathways are targets of Nrf2, and modulating the metabolism might contribute to this mechanism [85]. Here, NFE2L2 is linked to diabetes mellitus.